Singapore markets close in 5 hours 15 minutes

SciSparc Ltd. (SPRC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6730+0.0300 (+4.67%)
At close: 04:00PM EDT
0.6400 -0.03 (-4.90%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6430
Open0.6701
Bid0.6476 x 100
Ask0.7058 x 100
Day's range0.5952 - 0.7001
52-week range0.5952 - 15.8574
Volume3,963,437
Avg. volume1,050,062
Market cap2.189M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)-14.4300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

    The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuse

  • GlobeNewswire

    SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

    SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed a non-binding letter of intent (“LOI”) with an undisclosed biotechnology company to pursue the out-licensing of i

  • GlobeNewswire

    SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

    TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Na